REG - Ondine Biomedical - Ondine Presents Groundbreaking Findings

Ondine BiomedicalAnnouncement

10/06/2025 07:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250610:nRSJ1670Ma&default-theme=true

RNS Number : 1670M  Ondine Biomedical Inc.  10 June 2025

10(th) June 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Ondine Presents Groundbreaking Findings

Ondine presents ground-breaking findings in the fight against
multidrug-resistant pathogens at 19th World Congress of the International
Photodynamic Association

·    Photodisinfection shown to enhance the potency of many antibiotics,
including vancomycin, ciprofloxacin, and tetracycline, as well as antiseptics
such as benzalkonium chloride and chlorhexidine.

·    Combination of traditional antibiotics and photodynamic therapy
results in ultra-high lethality against completely drug-resistant pathogens.

Ondine Biomedical Inc. (AIM: OBI), a global leader in photodisinfection
technology, is presenting major advancements in the fight against
multidrug-resistant pathogens at the 19th World Congress of the International
Photodynamic Association (IPA) being held this week in Shanghai. The Company
has developed an intelligent robotic tool that leverages advanced AI-driven
algorithms to identify the most effective combinations of antimicrobial
therapies for eliminating a wide range of pathogens. This tool highlights the
powerful synergy between Ondine's light-activated photodisinfection technology
and existing antibiotics and antiseptics-a market valued at $80-100 billion
globally in 2024. 1-6 

The presentation, given by Ondine research scientist Micah Chavez, introduces
a novel methodology that uses a high-throughput robotic assay to characterize
interactions between legacy antimicrobials and potent photodisinfection. The
assay, designed specifically by the Company for this purpose, utilizes a new
optical checkerboard approach to conducting dozens of simultaneous
microbiological experiments with lethal pathogens in a safe and reproducible
manner, conforming to reporting requirements of the Clinical and Laboratory
Standards Institute (CLSI) and American Society for Microbiology (ASM)
guidelines.  AI-driven algorithms are used to select the most promising
combination of agents to team with photodisinfection for combined topical and
systemic attack against any given multi-drug-resistant pathogen.

Dr. Nicolas Loebel, President and Chief Technology Officer of Ondine, stated:

"Drug-resistant pathogens are a top priority for both the World Health
Organisation and the U.S. Centers for Disease Control and Prevention, already
contributing to millions of deaths and costing billions in healthcare and
productivity losses each year.  With resistance now observed across all known
antibiotic classes, new strategies are urgently needed. At IPA this year,
we're proud to be presenting compelling evidence that combining our
photodisinfection technology with conventional antimicrobials can multiply the
potency of both approaches, achieving ultra-high lethality, even against
completely drug-resistant strains.

"Our research shows that photodisinfection significantly enhances the efficacy
of antibiotics such as vancomycin, ciprofloxacin, and tetracycline, as well as
antiseptics like benzalkonium chloride and chlorhexidine. These findings point
to the intriguing possibility of dual-mode therapy for treatment of the
sickest patients, providing potent topical treatment with our
photodisinfection technology while at the same time boosting local efficacy of
systemic oral and injectable antimicrobials. This could potentially reshape
infection prevention strategies worldwide."

Ondine's photodisinfection platform technology underpins Steriwave®, the
Company's lead product, developed to prevent healthcare-associated infections
by targeting pathogens in the nasal cavity. Steriwave is in use at leading
healthcare institutions in Canada and the UK, including hospitals within the
CanHealth Network and the NHS, and a pivotal clinical trial is currently
underway to support FDA regulatory submission in the United States.

 

  Enquiries, please contact:

 

 Ondine Biomedical Inc.                                     www.ondinebio.com (https://ondinebio.com/)
 Carolyn Cross, CEO
Via Vane Percy & Roberts
 Strand Hanson Limited (Nominated & Financial Adviser)       +44 (0)20 7409 3494

James Harris, Richard Johnson
 RBC Capital Markets (Broker)                                +44 (0)20 7653 4000

Kathryn Deegan
 Vane Percy & Roberts (Media Contact)                       +44 (0)77 1000 5910
 Simon Vane Percy

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave(®). In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

 

 1  Antiseptics and Disinfectants Market Size to Worth USD 100.89 billion by
2033, at a CAGR of 9.5%. Straits Research. 21 Jan 2025.

 2  Antiseptics and Disinfectants Market: Global Industry Analysis and
Forecast (2024-2030). Maximize Market Research. Jan 2024.

 3  Antiseptic And Disinfectant Market Size, Share & Trends Analysis
Report By Type (Quaternary Ammonium Compounds), By Product (Enzymatic
Cleaners), By End-use, By Sales Channel, By Region, And Segment Forecasts,
2024 - 2030. Grand View Research. Accessed 9 June 2025.

 4  Antibiotics Market Size, Share & Trends Analysis Report By Action
Mechanism (Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors), By Drug
Class (Penicillin, Cephalosporin), By Type (Branded, Generic), And Segment
Forecasts, 2024 - 2030. Grand View Research. Accessed 9 Jun 2025.

 5  Antibiotics Market - Global Size & Upcoming Industry Trends 2024-2032.
Introspective Market Research. Accessed 9 Jun 2025.

 6  Antibiotics Market Size, Share, and Trends 2025 to 2034. Precedence
Research. Accessed 9 Jun 2025.
(https://www.precedenceresearch.com/antibiotics-market)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGLGDLSDBDGUG